1. Muoio DM, Newgard CB. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193-205.
2. Pratley RE. The early treatment of type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S2-9.
3. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81.
4. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol.2019;15(5):288-98.
5. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.
6. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60(10):2441-9.
7. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest.2005;115(5):1111-9.
8. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.
9. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15-8.
10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
11. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
12. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135- 51.
13. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-110.
14. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion.Pharmacol Rev. 2003;55(1):105-31.
15. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs.2003;63(18):1879-94.
16. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411.
17. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109.
18. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
19. Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.Drugs. 2014;74(15):1769-84.
20. Ghislain J, Poitout V. The Role and Future of FFA1 as a Therapeutic Target. Handb Exp Pharmacol. 2017;236:159-80.
21. Li Z, Xu X, Huang W, Qian H. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Med Res Rev. 2018;38:381-425.
22. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422(6928):173-6.
23. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al.The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303-11.
24. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab. 2005;289(4):E670-7.
25. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun. 2005;335(1):97-104.
26. Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett. 2014;24:2991-3000.
27. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2010;1(6):290-4.
28. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther. 2011;339(1):228-37.
29. Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol. 2013;170(3):568-80.
30. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. TAK- 875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403-11.
31. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36:245-50.
32. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab. 2016;18:925-9.
33. Wolenski FS, Zhu AZX, Johnson M, Yu S, Moriya Y, Ebihara T, et al. Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury. Toxicol Sci. 2017;157:50-61.
34. Sakuma K, Yabuki C, Maruyama M, Abiru A, Komatsu H, Negoro N, et al.Fasiglifam (TAK-875) has dual potentiating mechanisms via Galphaq- GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion. Pharmacol Res Perspect. 2016;4(3):e00237.
35. Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, Matsuda-Nagasumi K, et al. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013;8(10):e76280.
36. Brown SP, Dransfield PJ, Vimolratana M, Jiao X, Zhu L, Pattaropong V, et al.Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. ACS Med Chem Lett. 2012;3:726-30.
37. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One. 2012;7(10):e46300.
38. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012;82(5):843-59.
39. Pachanski MJ, Kirkland ME, Kosinski DT, Mane J, Cheewatrakoolpong B, Xue J, et al. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent. PLoS One. 2017;12(10):e0186033.
40. Ho JD, Chau B, Rodgers L, Lu F, Wilbur KL, Otto KA, et al. Structural basis for GPR40 allosteric agonism and incretin stimulation. Nat Commun. 2018;9(1):1645.
41. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379(6560):69-72.
42. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146(12):5120-7.
43. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136:849-70.
44. Aida J, Yoshitomi Y, Hitomi Y, Noguchi N, Hirata Y, Furukawa H, et al. (2015) WO 2015/020184.
45. Ueno H, Ito R, Abe SI, Ookawara M, Miyashita H, Ogino H, et al. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. J Pharmacol Exp Ther. 2019;370(2):172-81.
46. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, et al.Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 1990;127:126-32.
47. Lee YC, Asa SL, Drucker DJ. Glucagon gene 5'-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem. 1992;267:10705-8.
48. American Diabetes Association. 14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S144-51.
49. Portha B, Giroix M, Serradas P, Movassat J, Bailbe D and Kergoat M (2003) The neonatally streptozotocin-induced (n-STZ) diabetic rats, a family of NIDDM models, in Animal Models in Diabetes pp 231-51, CRC Press.
50. Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy. 2004;24:606-20.
51. Kogame A, Lee R, Pan L, Sudo M, Nonaka M, Moriya Y, et al. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2018:1-13.
52. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, et al. A multiple- ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92:29-39.
53. Moran TH. Gut peptide signaling in the controls of food intake. Obesity (Silver Spring). 2006;14 Suppl 5:250S-253S.
54. Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014;5:4-14.
55. Gorski JN, Pachanski MJ, Mane J, Plummer CW, Souza S, Thomas-Fowlkes BS, et al. GPR40 reduces food intake and body weight through GLP-1. Am J Physiol Endocrinol Metab. 2017;313(1):E37-47.
56. Camilleri M. Peripheral mechanisms in appetite regulation. Gastroenterology.2015;148(6):1219-33.
57. Schwartz GJ. Integrative capacity of the caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1275-80.
58. Grill HJ, Hayes MR. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int J Obes (Lond). 2009;33 Suppl 1:S11-5.
59. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon- like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem- hypothalamic pathway. Brain Res. 2005;1044(1):127-31.
60. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology. 2005;146(9):3748-56.
61. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science. 1981;213(4511):1036- 7.
62. Barrachina MD, Martínez V, Wang L, Wei JY, Taché Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A. 1997;94(19):10455-60.
63. Miwatashi S, Miyamoto Y, Watanabe K, Yoshitomi Y, Hitomi Y, Aida J, et al. (2018) WO2018181847A1.
64. Ueno H, Ito R, Abe SI, Ogino H, Maruyama M, Miyashita H, et al. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. PLoS One. 2019;14(9):e0222653.
65. Matsuda-Nagasumi K, Takami-Esaki R, Iwachidow K, Yasuhara Y, Tanaka H, Ogi K, et al. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition. Diabetes Obes Metab. 2013;15(6):538-45.
66. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. A new genetically obese- hyperglycemic rat (Wistar fatty). Diabetes. 1981;30(12):1045-50.
67. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123(4):1120-8.
68. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-88.
69. Gram DX, Hansen AJ, Deacon CF, Brand CL, Ribel U, Wilken M, et al. Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. Eur J Pharmacol. 2005;509(2-3):211-7.
70. Paxinos, G., & Watason, C. (2004). The rat brain (5th ed.). San Diego, CA:Elsevier Academic Press.
71. Egerod KL, Petersen N, Timshel PN, Rekling JC, Wang Y, Liu Q, et al. Profiling of G protein-coupled receptors in vagal afferents reveals novel gut-to-brain sensing mechanisms. Mol Metab. 2018;12:62-75.
72. Iwasaki Y, Shimomura K, Kohno D, Dezaki K, Ayush EA, Nakabayashi H, et al.Insulin Activates Vagal Afferent Neurons Including those Innervating Pancreas via Insulin Cascade and Ca(2+) Influx: Its Dysfunction in IRS2-KO Mice with Hyperphagic Obesity. PLoS One. 2013;8(6):e67198.
73. Iwasaki Y, Goswami C, Yada T. Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. Neuropeptides. 2017;65:77-82.
74. Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T, et al. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J Neurochem. 2012;121(1):66- 76.
75. Zhang SY, Li J, Xie X. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119. Acta Pharmacol Sin. 2014;35:540-8.
76. Rajagopal S, Shenoy SK. GPCR desensitization: Acute and prolonged phases. Cell Signal. 2018;41:9-16.
77. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, et al. High- resolution structure of the human GPR40 receptor bound to allosteric agonist TAK- 875. Nature. 2014;513(7516):124-7.
78. Lu J, Byrne N, Wang J, Bricogne G, Brown FK, Chobanian HR, et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat Struct Mol Biol. 2017;24(7):570-7.
79. Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, Di Salvo J, et al. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab. 2014;4(1):3-14.
80. Furukawa H, Miyamoto Y, Hirata Y, Watanabe K, Hitomi Y, Yoshitomi Y, et al.Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2- Carbamoylphenyl Piperidine Moiety. J Med Chem. 2020;63(18):10352-79.
81. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57(9):2280- 7.
82. Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, et al.Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151.
83. Chepurny OG, Bonaccorso RL, Leech CA, Wöllert T, Langford GM, Schwede F, et al. Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Sci Rep. 2018;8:3749
84. Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsboll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co- agonists in the Treatment of NAFLD. Front Endocrinol (Lausanne). 2018;9:649.
85. Ookawara M, Matsuda K, Watanabe M, Moritoh Y. The GPR40 Full Agonist SCO- 267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. J Pharmacol Exp Ther. 2020;375(1):21-7.
86. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749-57.
87. Han J, Sun L, Huang X, Li Z, Zhang C, Qian H, et al. Novel coumarin modified GLP- 1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. Br J Pharmacol. 2014;171(23):5252-64.
88. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, et al.Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-404.
89. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP- 1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011;152(8):3103-12.
90. Xiong Y, Swaminath G, Cao Q, Yang L, Guo Q, Salomonis H, et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol. 2013;369(1-2):119-29.
91. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. Diabetes. 2016;65(1):34-43.
論文の公開元へ
